Nyxoah Q2 revenue surges on U.S. growth, but margins drop
Nyxoah Q2 revenue surges on U.S. growth, but margins drop
Overview
Belgium medical device maker's Q2 revenue rose sharply yr/yr on U.S. commercialization
Gross margin for Q2 declined to 60% from 63% due to higher U.S. revenue mix
Company maintained full-year revenue and margin outlook, raised operating expense guidance
Outlook
Nyxoah expects 2026 worldwide net revenue of €36 mln to €40 mln
Company sees 2026 gross margin in the range of 60% to 62%
Nyxoah now expects 2026 total operating expenses of €99 mln to €102 mln
Result Drivers
U.S. COMMERCIALIZATION - Co said revenue growth was driven by expansion of U.S. commercialization activities following FDA approval
SALES FORCE AND ACCOUNT ACTIVATION - Co cited increased number of active sales reps, new surgeon training, and doubling of active accounts as supporting launch momentum
REIMBURSEMENT ENVIRONMENT - Co said 100% approval rate on prior authorization submissions and clarity on coding supported accelerating U.S. revenue growth
Company press release: ID:nGNE2CHRHm
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Share |
| EUR 0.58 |
|
Q2 Gross Margin |
| 60.00% |
|
Q2 Gross Profit |
| EUR 4.58 mln |
|
Q2 Loss Per Basic Share |
| EUR 0.58 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Nyxoah SA is €5.30, about 323.3% above its August 5 closing price of €1.25
Reuters Recommended Reads
Aug 3 - Inspire Medical Q2 revenue falls less than expected
Aug 5 - UK's LivaNova Q2 revenue beats estimates; lifts 2026 outlook
Aug 5 - Insulet Q2 revenue beats on higher Omnipod sales
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Nyxoah SA
See all newsBelgium's Nyxoah Q3 revenue rises on US commercialization
Brief: Nyxoah SA Q3 Gross Profit EUR 5.785 Million
Brief: Nyxoah SA Submits Pma Supplement To FDA To Expand Genio Indication To Complete Concentric Collapse Patients
Brief: Nyxoah Says Co Appoints Liam Kelly As Chief Executive Officer Effective October 1
Brief: Cvrx Appoints John Landry As Chief Financial Officer